Back

Kenya Reports First Imported Case of Bundibugyo Ebola

lite News Desk 2 min read

At a glance

  • Kenya confirmed its first imported Bundibugyo Ebola case in October 2026.
  • The patient had travelled from the Democratic Republic of Congo via Uganda.
  • Kenya notified WHO and implemented required health measures.

Kenya identified its first imported case of Bundibugyo Ebola Virus Disease in early October 2026, involving a citizen returning from the Democratic Republic of Congo. The development follows an ongoing outbreak in the region that had already prompted international health alerts.

The patient entered Kenya by road through Uganda before arriving in Nairobi by air on 3 October 2026. Upon arrival, the individual was isolated at Nairobi Hospital and later transferred to a designated isolation facility for further management.

Laboratory testing at both the National Virology Reference Laboratory and the Kenya Medical Research Institute confirmed the presence of Bundibugyo Ebola Virus in the patient. The Ministry of Health reported that the patient died after the diagnosis was established.

Kenya’s Ministry of Health stated that the World Health Organization was notified of the case, in accordance with the International Health Regulations (2005). These regulations require immediate reporting and the implementation of isolation, case management, diagnostic confirmation, and contact tracing within 24 hours of detection.

What the numbers show

  • Over 652,000 travellers screened in Kenya as of 6 October 2026.
  • 267 suspected Ebola samples tested in the country.
  • Approximately 5,000 health workers trained on Ebola response.

The World Health Organization declared the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo and Uganda a Public Health Emergency of International Concern on 17 May 2026. This declaration triggered additional monitoring and reporting requirements for countries in the region.

As part of its response, Kenya increased surveillance at entry points and expanded training for healthcare workers to improve detection and management of potential Ebola cases. These actions were part of broader efforts to contain the spread of the virus and meet international reporting standards.

WHO has advised against imposing travel or trade restrictions related to the Democratic Republic of the Congo, Uganda, or Kenya based on the available information. The organization continues to support affected countries with technical guidance and coordination.

* This article is based on publicly available information at the time of writing.

More from Health & Biotech

  1. The FDA approved Jaypirca for adults with untreated CLL or SLL without 17p deletion, marking it as the first non-covalent BTK inhibitor.

  2. A filing describes Roche’s NDA acceptance for fenebrutinib on September 30, 2026, according to the regulator. Priority review status was granted.

  3. A filing describes the approval of a new treatment for Parkinson's disease, according to the regulator. The decision was made on September 25, 2026.

  4. The FDA has approved Pasatru for treating heterotopic ossification lesions in adults with fibrodysplasia ossificans progressiva, according to the regulator.

  5. A panel voted 10-0 to endorse the Galleri test for detecting multiple cancers through a single blood sample, according to the regulator.